Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Connect Twitter with Market Wire News

CBAY News and Press CymaBay Therapeutics Inc.


home / stock / cbay / cbay news

RSS
CBAY CBAY Quote CBAY Short CBAY News CBAY Articles CBAY Message Board
  • CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously a...

    • January 30, 2023 08:00:00 am
    • |
    • GlobeNewswire
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay gains on pricing of $85.05M public offering

    CymaBay Therapeutics ( NASDAQ: CBAY ) announces the pricing the previously announced public offering of common stock and pre-funded warrants. The company to sell 10M shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. ...

    • January 24, 2023 07:37:00 am
    • |
    • SeekingAlpha
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay stock pops 7% after launching stock and warrants offering

    CymaBay Therapeutics ( NASDAQ: CBAY ) +7.6% aftermarket on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaB...

    • January 23, 2023 04:39:12 pm
    • |
    • SeekingAlpha
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay join hands with Kaken to develop, commercialize Seladelpar

    CymaBay Therapeutics ( NASDAQ: CBAY ) has entered into a collaboration and license pact with Kaken Pharmaceutical for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis. The advances str...

    • January 09, 2023 02:52:24 am
    • |
    • SeekingAlpha
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

    Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Cy...

    • January 08, 2023 12:00:00 pm
    • |
    • GlobeNewswire
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay Therapeutics: Undiscovered Opportunity

    Summary 100% technical buy signals. 13 new highs and up 84.95% in the last month. Wall Street price targets from $8 to $14. The Chart of the Day belongs to the biopharma company CymaBay Therapeutics (CBAY). I found the stock by using Barchart's powerful screening funct...

    • December 31, 2022 06:57:06 am
    • |
    • SeekingAlpha
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Call Transcript

    CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Conference Call November 14, 2022 16:30 ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - Chief Scientific Officer and President, R&D Dennis Kim...

    • November 15, 2022 04:47:05 am
    • |
    • SeekingAlpha
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02

    CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q3 GAAP EPS of -$0.28 beats by $0.02 . Held $153.4 million in cash, cash equivalents and investments as of September 30, 2022. For further details see: CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02...

    • November 14, 2022 04:17:39 pm
    • |
    • SeekingAlpha
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update

    NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the ...

    • November 14, 2022 04:06:00 pm
    • |
    • GlobeNewswire
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
  • CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

    NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

    • November 07, 2022 04:05:00 pm
    • |
    • GlobeNewswire
    • |
      • CBAY Stock
      • CBAY Quote
      • CBAY Short
      • CBAY News
      • CBAY Articles
      • CBAY Message Board
Next 10
Stock Information

CymaBay Therapeutics Inc. Company Name:

CBAY Stock Symbol:

NASDAQ Market:

CymaBay Therapeutics Inc. Website:

Get CBAY Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

Connect Twitter with Market Wire News
RECENT CBAY NEWS
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2023 Market Wire News